Table 3. Summary of bevacizumab-related adverse events.

Bevacizumab-related adverse event	CisPemBev, N=131, n [%]			CarPacBev, N=66, n [%]
	Any grade	Grade 3		Any grade	Grade 3
Hemorrhage/bleeding
Epistaxis	19 [15]	0 [0]		18 [27]	0 [0]
Duodenum hemorrhage	1 [1]	0 [0]		0 [0]	0 [0]
Esophagus hemorrhage	0 [0]	0 [0]		1 [2]	0 [0]
Oral cavity hemorrhage	1 [1]	0 [0]		0 [0]	0 [0]
Anal hemorrhage	0 [0]	0 [0]		1 [2]	0 [0]
Hemorrhoidal hemorrhage	1 [1]	0 [0]		1 [2]	0 [0]
Tracheal hemorrhage	1 [1]	1 [1]		0 [0]	0 [0]
Bronchopulmonary hemorrhage	1 [1]	0 [0]		0 [0]	0 [0]
Vascular
Thrombosis	3 [2]	1 [1]		1 [2]	0 [0]
Cardiac general
Hypertension	93 [71]	39 [30]		36 [55]	15 [23]
Congestive heart failure	1 [1]	0 [0]		0 [0]	0 [0]
Metabolic/laboratory
Proteinuria	66 [50]	0 [0]		36 [55]	0 [0]

There were no grade 4 or 5 bevacizumab-related events. Common Terminology Criteria for Adverse Events v3.0. CarPacBev, carboplatin + paclitaxel + bevacizumab; CisPemBev, cisplatin + pemetrexed + bevacizumab.